June 25, 2023

Dermagnostix completes IRB approved clinical study at NEA Expo

Dermagnostix participated in the National Eczema Association Expo in Orlando, Florida, June 23-25, 2023. During the event, Dermagnostix successfully completed an observational sample collection study to assess the molecular markers present in non-communicable chronic inflammatory skin disease (e.g. eczema, atopic dermatitis).

The goal of the sample collection study was to quantitatively assess the presence of molecular markers in subject’s skin collected non-invasively. Eczema is a characterized by a complex pathogenesis and broad variety of different phenotypes that are not yet sufficiently considered in clinical practice. To allow for individual treatment regimens, molecular tools are needed to identify disease subtypes.